Euroopan unioni - malta - EMA (European Medicines Agency)

ammtek - glibenclamide - diabetes mellitus - drogi użati fid-dijabete - amglidia huwa indikat għall-kura ta ' trabi tat-twelid dijabete mellitus, għall-użu fit-trabi tat-twelid, trabi u tfal. sulphonylureas bħal amglidia ntwerew li huma effikaċi fil-pazjenti bil-mutazzjonijiet fil-kodiċi tal-ġene għall-taċ-ċelloli β-potassju sensittiv għal atp kanal u tal-kromożomi 6q24 relatati mal-għaddiena neonatali tad-dijabete mellitus.

Euroopan unioni - malta - EMA (European Medicines Agency)

viatris limited - insulina glargine - diabetes mellitus - drogi użati fid-dijabete - trattament tad-dijabete mellitus f'adulti, adolexxenti u tfal ta 'sentejn u aktar.

Euroopan unioni - malta - EMA (European Medicines Agency)

nova laboratories ireland limited - hydroxycarbamide - anemija, sickle cell - aġenti antineoplastiċi - il-prevenzjoni ta vaso-okklusivi komplikazzjonijiet tal-marda taċ-ċelluli sickle fil-pazjenti ta ' aktar minn 2 snin ta'età.

Euroopan unioni - malta - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artrite, rewmatika - immunosoppressanti - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Euroopan unioni - malta - EMA (European Medicines Agency)

gilead sciences ireland uc, galapagos nv - filgotinib maleate - artrite, rewmatika - immunosoppressanti - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

Euroopan unioni - malta - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatite, atopika - preparazzjonijiet oħra dermatoloġiċi - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.